Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying
Mary M. Sweeney, Sandeep M. Nayak, Ethan Hurwitz, Lisa N. Mitchell, Thomas Cody Swift, Roland R. Griffiths
PLoS One August 24, 2022 DOI: 10.1371/journal.pone.0271926 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 3,192 |
| Population | Individuals who reported an experience that altered their beliefs about death, occasioned by a psychedelic drug or a near-death or other non-ordinary experience |
| Topics | LSD Mysticism Psilocybin Near-death experience |
| Keywords | Clinical psychology Hallucinogen |
| Citations | 60 |
| Key findings | Both psychedelic and non-drug experiences that change death attitudes produce similar reductions in fear of death and high ratings of personal meaning, though psychedelic experiences show greater mystical and near-death features. |
Abstract
Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direct comparisons of these phenomena. This study directly compared psychedelic occasioned and non-drug experiences which altered individuals’ beliefs about death. Individuals who reported an experience that altered their beliefs about death occasioned by either a psychedelic drug or a near-death or other non-ordinary experience completed an online survey. Circumstances of the experience, mystical and near-death subjective features, changes in attitudes about death, and other persisting effects were evaluated. The study sample ( n = 3192) included five groups: non-drug near-death or other non-ordinary experiences ( n = 933), and drug experiences occasioned by lysergic acid diethylamide (LSD) ( n = 904), psilocybin ( n = 766), ayahuasca ( n = 282), or N , N- dimethyltryptamine (DMT) ( n = 307). Analyses of differences in experiences were adjusted statistically for demographic differences between groups. Compared to the psychedelic groups, the non-drug group was more likely to report being unconscious, clinically dead, and that their life was in imminent danger. The groups were remarkably similar in the reported changes in death attitudes attributed to the experience, including a reduced fear of death and high ratings of positive persisting effects and personal meaning, spiritual significance, and psychological insight. Although both psychedelic and non-drug participants showed robust increases on standardized measures of mystical and near-death experiences, these measures were significantly greater in the psychedelic participants. Non-drug participants were more likely to rate their experiences as the single most meaningful of their lives. Comparing across psychedelic substances, ayahuasca and DMT groups tended report stronger and more positive enduring consequences of the experience than the psilocybin and LSD groups, which were largely indistinguishable. These data provide a detailed characterization and comparison of psychedelic occasioned and non-drug experiences that changed attitudes about death and suggest the importance of future prospective psychedelic administration studies.
Comparable studies
Other cross-sectional and survey studies on LSD, most cited first.
Citations in the library
Cited by 50
- Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences Frontiers in Psychology June 14, 2023
- A Transformative Trip? Experiences of Psychedelic Use Neuroethics June 20, 2024
- Psychedelic experiences and long-term spiritual growth: a systematic review Current Psychology July 12, 2024
- A scoping review for building a criticality-based conceptual framework of altered states of consciousness Frontiers in Systems Neuroscience May 25, 2023
- Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being Death Studies February 2, 2023
and 45 more in the library
Cites 41
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 36 more in the library